When more is less: Emergent suppressive interactions in three-drug combinations

BMC Microbiology

Volumn 17, Issue 1, 2017, Pages

  Beppler, Casey ^a   Tekin, Elif ^b   White, Cynthia ^a   Mao, Zhiyuan ^a   Miller, Jeffrey H ^b   Damoiseaux, Robert ^a   Savage, Van M ^a,b,c   Yeh, Pamela J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANTA FE INSTITUTE   (United States)

Author keywords

Antagonism; Antibiotics; Drug resistance; Higher order interactions; Multiple stressors

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOXITIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; NITROFURANTOIN; STREPTOMYCIN; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONCENTRATION RESPONSE; DRUG EFFICACY; ESCHERICHIA COLI; GROWTH INHIBITION; NONHUMAN; PREVALENCE; STAPHYLOCOCCUS EPIDERMIDIS; BACTERIUM; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 85018775866     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-017-1017-3     Document Type: Article

References (49)

1. World Health Organization. Antimicrobial resistance: Global report on surveillance 2014 2014.
2. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71-109.
3. Davies J, Davies D. Origins and evolution of Antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417-33.
4. Kalan L, Wright G. Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Reviews Mol Med. 2011;13:e5.
5. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A. 2008;105:13977-81.
6. Loewe S. Die Mischiarnei. Klin Wochenschr. 1927;6:1077-85.
7. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol. 1939;26:585-615.
8. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R. Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol. 2009;7:460-6.
9. Klastersky J, Cappel R, Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother. 1972;2:470-5.
10. Fraser TR. Lecture on the antagonism between the actions of active substances. Br Med J. 1872;2:457-9.
11. Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat Genet. 2006;38:489-94.
12. Jawetz E, Smith L. Combinations of antimicrobials. Calif Med. 1972;117:40-&.
13. Chait R, Craney A, Kishony R. Antibiotic interactions that select against resistance. Nature. 2007;446:668-71.
14. Michel JB, Yeh PJ, Chait R, Moellering RC, Kishony R. Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A. 2008;105:14918-23.
15. Torella JP, Chait R, Kishony R. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol. 2010;6:e1000796.
16. Cokol M, Weinstein ZB, Yilancioglu K, Tasan M, Doak A, Cansever D, Mutlu B, Li S, Rodriguez-Esteban R, Akhmedov M, et al. Large-scale identification and analysis of suppressive drug interactions. Chem Biol. 2014;21:541-51.
17. Wood K, Nishida S, Sontag ED, Cluzel P. Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc Natl Acad Sci U S A. 2012;109:12254-9.
18. Beppler C, Tekin E, Mao Z, White C, McDiarmid C, Vargas E, Miller JH, Savage VM, Yeh PJ. Uncovering emergent interactions in three-way combinations of stressors. J R Soc Interface. 2016;13:125.
19. Tekin E, Beppler C, White C, Mao Z, Savage VM, Yeh PJ. Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface. 2016;13:119.
20. Datsenko K, Wanner B. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97:6640-5.
21. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko K, Tomita M, Wanner B, Mori H. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006;2:2006.0008.
22. Keren I, Wu Y, Inocencio J, Mulcahy JR, Lewis K. Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science. 2013;339:1213-6.
23. Cohen NR, Ross CA, Jain S, Shapiro RS, Gutierrez A, Belenky P, Li H, Collins JJ. A role for the bacterial GATC methylome in antibiotic stress survival. Nat Genet. 2016;48:581-6.
24. Gagarinova A, Stewart G, Samanfar B, Phanse S, White CA, Aoki H, Deineko V, Beloglazova N, Yakunin AF, Golshani A, et al. Systematic genetic screens reveal the dynamic global functional Organization of the Bacterial Translation Machinery. Cell Rep. 2016;17:904-16.
25. Scott GM, Kyi MS. Handbook of essential Antibiotics. Amsterdam: Harwood Academic; 2001.
26. Zhou A, Kang TM, Yuan J, Beppler C, Nguyen C, Mao Z, Nguyen MQ, Yeh P, Miller JH. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother. 2015;59:276-81.
27. Welch H. Principles and practice of antibiotic therapy. New York: Medical Encyclopedia, Inc; 1954.
28. Davies J, Spiegelman GB, Yim G. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol. 2006;9:445-53.
29. Yim G, Wang HH, Davies J. The truth about antibiotics. Int J Med Microbiol. 2006;296:163-70.
30. Linares JF, Gustafsson I, Baquero F, Martinez JL. Antibiotics as intermicrobial signaling agents instead of weapons. Proc Natl Acad Sci U S A. 2006;103:19484-9.
31. Ocampo PS, Lázár V, Papp B, Arnoldini M, Abel zur Wiesch P, Busa-Fekete R, Fekete G, Pál C, Ackermann M, Bonhoeffer S. Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother. 2014;58:4573-82.
32. Segre D, DeLuna A, Church G, Kishony R. Modular epistasis in yeast metabolism. Nat Genet. 2005;37:77-83.
33. Sanjuán R, Elena SF. Epistasis correlates to genomic complexity. Proc Natl Acad Sci U S A. 2006;103:14402-5.
34. He X, Qian W, Wang Z, Li Y, Zhang J. Prevalent positive epistasis in Escherichia coli and Saccharomyces cerevisiae metabolic networks. Nat Genet. 2010;42:272-6.
35. Zimmer A, Katzir I, Dekel E, Mayo AE, Alon U. Prediction of multidimensional drug dose responses based on measurements of drug pairs. Proc Natl Acad Sci U S A. 2016;113:10442-7.
36. Glimm J, Jaffe A. Quantum physics: a functional integral point of view. 2nd ed. Berlin, New York: Springer-Verlag; 1987.
37. Kendall MG, Stuart A. The advanced theory of statistics. London: Griffin; 1969.
38. Bollenbach T, Quan S, Chait R, Kishony R. Non-optimal microbial response to antibiotics underlies suppressive drug interactions. Cell. 2009;139:707-18.
39. Demchok J, Meletiadis J, Roilides E, Walsh T. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses. 2010;53:239-45.
40. de Oliveira CE, Stamford TL, Gomes Neto NJ, de Souza EL. Inhibition of Staphylococcus aureus in broth and meat broth using synergies of phenolics and organic acids. Int J Food Microbiol. 2010;137:312-6.
41. de Vos MG, Bollenbach T. Suppressive drug interactions between antifungals. Chem Biol. 2014;21:439-40.
42. Kelsic ED, Zhao J, Vetsigian K, Kishony R. Counteraction of antibiotic production and degradation stabilizes microbial communities. Nature. 2015;521:516-9.
43. Lee JT, Taylor MB, Shen A, Ehrenreich IM. Multi-locus genotypes underlying temperature sensitivity in a Mutationally induced trait. PLoS Genet. 2016;12:e1005929.
44. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2002;70:204-10.
45. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother. 2003;47:1301-7.
46. Edgar R, Friedman N, Molshanski-Mor S, Qimron U. Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol. 2012;78:744-51.
47. Wagner PL, Waldor MK. Bacteriophage control of bacterial virulence. Infect Immun. 2002;70:3985-93.
48. Bernhardt TG, Wang IN, Struck DK, Young R. A protein antibiotic in the phage Qbeta virion: diversity in lysis targets. Science. 2001;292:2326-9.
49. Kadouri DE, To K, Shanks RM, Doi Y. Predatory bacteria: a potential ally against multidrug-resistant gram-negative pathogens. PLoS ONE. 2013;8:e63397.